| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1042560844 |
| P356 | DOI | 10.1007/S10637-013-9970-7 |
| P698 | PubMed publication ID | 23665866 |
| P2093 | author name string | R H Wilson | |
| M Morris | |||
| C Purcell | |||
| J Millar | |||
| D Law | |||
| M M Eatock | |||
| R Gallagher | |||
| C R James | |||
| E Napier | |||
| R C Turkington | |||
| P2860 | cites work | Chemotherapy for advanced gastric cancer | Q24236634 |
| Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors | Q45291138 | ||
| Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. | Q46474270 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma | Q46886155 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| The proteasome inhibitor PS-341 in cancer therapy. | Q54077971 | ||
| Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. | Q54572120 | ||
| Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB | Q64381570 | ||
| Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer | Q72729402 | ||
| H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells | Q73977784 | ||
| Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue | Q77372895 | ||
| Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug | Q79777795 | ||
| A phase II study of carboplatin and paclitaxel in esophageal cancer | Q80107223 | ||
| The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma | Q80419561 | ||
| NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis | Q24554454 | ||
| Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer | Q24649684 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| The proteasome: a novel target for cancer chemotherapy | Q28215095 | ||
| Activators and target genes of Rel/NF-kappaB transcription factors | Q29547882 | ||
| TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB | Q29614706 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer | Q33366089 | ||
| A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies | Q33371505 | ||
| The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study | Q33378105 | ||
| A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer | Q33378878 | ||
| Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation | Q33855223 | ||
| Proteasome inhibitors: a novel class of potent and effective antitumor agents. | Q33864458 | ||
| The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. | Q34293383 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
| NF-κB addiction and its role in cancer: 'one size does not fit all'. | Q35120893 | ||
| Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib | Q35124101 | ||
| Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions. | Q36474355 | ||
| Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. | Q36613503 | ||
| Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. | Q36984165 | ||
| Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells | Q37291635 | ||
| Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). | Q37593877 | ||
| NF-κB and the link between inflammation and cancer | Q37995696 | ||
| A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma | Q39860629 | ||
| Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. | Q39999852 | ||
| Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells | Q40086725 | ||
| Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants | Q40273672 | ||
| Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. | Q40342000 | ||
| Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus | Q40417530 | ||
| Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer | Q40531487 | ||
| A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. | Q40643409 | ||
| Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor kappa B in human gastric carcinoma tissue | Q41877326 | ||
| Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. | Q43590541 | ||
| Coronary spasm induced by capecitabine | Q43658220 | ||
| Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial | Q43877542 | ||
| Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil | Q44035791 | ||
| Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts | Q44615211 | ||
| P433 | issue | 2 | |
| P921 | main subject | carboplatin | Q415588 |
| capecitabine | Q420207 | ||
| phase I clinical trial | Q5452194 | ||
| P304 | page(s) | 250-260 | |
| P577 | publication date | 2013-05-11 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma | |
| P478 | volume | 32 |
Search more.